Adage Capital Partners
CRVS icon

Adage Capital Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Adage Capital Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
+750,000
New +$12M 0.02% 670
2021
Q4 		– Sell
-200,000
Closed -$968K – 1038
2021
Q3 		$968K Buy
+200,000
New +$592K ﹤0.01% 914

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners's CRVS Position: Q1 2026 in Review

Adage Capital Partners opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 750,000 shares worth $11M. The stake represents 0.02% of the portfolio and ranks #670 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in CRVS as recently as Q3 2021.

Adage Capital Partners first reported a position in CRVS in Q3 2021 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Adage Capital Partners held 750,000 shares of Corvus Pharmaceuticals worth $11M as of Q1 2026.
  • Corvus Pharmaceuticals was a new Adage Capital Partners position in Q1 2026.
  • Corvus Pharmaceuticals made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #670 holding.
  • Adage Capital Partners first reported a position in Corvus Pharmaceuticals in Q3 2021 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.